Kinnate Biopharma Inc. (KNTE) Financial Statements (2024 and earlier)

Company Profile

Business Address 11975 EL CAMINO REAL, STE 101
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments167,576,000184,703,000200,981,000201,475,000230,979,000232,995,000
Cash and cash equivalents51,662,00034,507,00073,570,00029,261,00034,502,00035,065,000
Short-term investments115,914,000150,196,000127,411,000172,214,000196,477,000197,930,000
Restricted cash and investments    25,725,00026,469,00029,420,000
Other undisclosed current assets2,725,0003,897,0004,307,0003,637,0003,727,0004,718,000
Total current assets:170,301,000188,600,000205,288,000230,837,000261,175,000267,133,000
Noncurrent Assets
Operating lease, right-of-use asset2,660,0002,958,0003,170,0003,377,0003,581,0003,781,000
Property, plant and equipment2,470,0002,667,0002,877,0003,071,0003,171,0003,292,000
Long-term investments and receivables12,762,00019,579,00030,203,00039,139,00031,097,00046,604,000
Long-term investments12,762,00019,579,00030,203,00039,139,00031,097,00046,604,000
Restricted cash and investments371,000371,000371,000371,000371,000371,000
Deferred costs     641,000641,000
Other noncurrent assets2,145,0001,960,0001,971,0002,031,0002,097,0002,074,000
Total noncurrent assets:20,408,00027,535,00038,592,00047,989,00040,958,00056,763,000
TOTAL ASSETS:190,709,000216,135,000243,880,000278,826,000302,133,000323,896,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,905,00014,814,00017,172,00016,176,00018,117,00012,792,000
Employee-related liabilities3,740,0002,164,000
Accounts payable2,929,0002,696,0004,451,0002,970,0003,058,0002,016,000
Accrued liabilities11,976,00012,118,00012,721,00013,206,00011,319,0008,612,000
Other undisclosed current liabilities869,000959,000983,000991,000(2,774,000)(1,328,000)
Total current liabilities:15,774,00015,773,00018,155,00017,167,00015,343,00011,464,000
Noncurrent Liabilities
Long-term debt and lease obligation:     3,449,0003,703,000
Liabilities, other than long-term debt2,515,0002,742,0002,963,0003,191,000  
Operating lease, liability2,515,0002,742,0002,963,0003,191,0003,449,0003,703,000
Other undisclosed noncurrent liabilities     (3,449,000)(3,703,000)
Total noncurrent liabilities:2,515,0002,742,0002,963,0003,191,0003,449,0003,703,000
Total liabilities:18,289,00018,515,00021,118,00020,358,00018,792,00015,167,000
Temporary equity, carrying amount    35,000,00035,000,00035,000,000
Equity
Equity, attributable to parent172,420,000197,620,000222,762,000223,468,000248,341,000273,729,000
Common stock5,0005,0005,0004,0004,0004,000
Additional paid in capital527,516,000522,178,000515,524,000484,237,000478,696,000473,525,000
Accumulated other comprehensive loss(147,000)(342,000)(464,000)(1,410,000)(2,559,000)(2,737,000)
Accumulated deficit(354,954,000)(324,221,000)(292,303,000)(259,363,000)(227,800,000)(197,063,000)
Total equity:172,420,000197,620,000222,762,000223,468,000248,341,000273,729,000
TOTAL LIABILITIES AND EQUITY:190,709,000216,135,000243,880,000278,826,000302,133,000323,896,000

Income Statement (P&L) (USD)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Operating expenses(33,089,000)(34,135,000)(34,653,000)(32,684,000)(31,372,000)(27,406,000)
Operating loss:(33,089,000)(34,135,000)(34,653,000)(32,684,000)(31,372,000)(27,406,000)
Nonoperating income2,356,0002,217,0001,713,0001,121,000635,000337,000
Loss from continuing operations:(30,733,000)(31,918,000)(32,940,000)(31,563,000)(30,737,000)(27,069,000)
Loss before gain (loss) on sale of properties:(30,737,000)(27,069,000)
Net loss available to common stockholders, diluted:(30,733,000)(31,918,000)(32,940,000)(31,563,000)(30,737,000)(27,069,000)

Comprehensive Income (USD)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(30,733,000)(31,918,000)(32,940,000)(31,563,000)(30,737,000)(27,069,000)
Other comprehensive income (loss) 195,000122,000946,000 178,000(557,000)
Other undisclosed comprehensive income   1,149,000  
Comprehensive loss:(30,538,000)(31,796,000)(31,994,000)(30,414,000)(30,559,000)(27,626,000)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(30,538,000)(31,796,000)(31,994,000)(30,414,000)(30,559,000)(27,626,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: